Terminated
PHASE2
INTERVENTIONAL
NCT02154087
A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Assess the influence of HP802-247 on biochemical and cellular markers of inflammation in chronic venous leg ulcers
Interventions
Name:
HP802-247
Type:
BIOLOGICAL
Description:
260 µL (130 µL, one spray, of each component) containing 0.5 x 10.6 cells per mL, alternating weekly with Vehicle
Primary Outcomes
Measure:
Determine Change From Baseline in Cell Numbers in Subjects With VLU Following the First Dose of HP802-247
TimeFrame:
Wound fluid samples were to be collected one week after the initial dose of HP802-247.
Description:
The following mediators were to be measured for the chronic ulcer stage: IL-1β, IL-6, TNF-α, IFN, MMP-2, and MMP-9, and the following for the resolving ulcer stage: PGE-2, Lipoxin, GM-CSF, TGFβ, IL-10, LL-37, Indoleamine 2,3-Dioxygenase (IDO), and Arginase (ARG-1). Each of the soluble mediators were to be plotted versus measurement time point \[i.e., (pre-study run-in visit (RV)1), baseline (RV3), study visit (SV)2, and SV3\]) and by subjects' quartile of percent reduction (%) in target wound area at SV3 from baseline (RV3).
Trial Information
NCT ID
NCT02154087
Status
Terminated
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Healthpoint
Last Updated
December 15, 2025